Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance

AIDS. 2020 Nov 15;34(14):2152-2155. doi: 10.1097/QAD.0000000000002687.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Cerebrospinal Fluid / virology*
  • Drug Resistance, Multiple, Viral
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects*
  • Humans
  • Male
  • Middle Aged
  • RNA, Viral
  • Viral Load / drug effects
  • Virus Replication / drug effects*

Substances

  • Anti-HIV Agents
  • Antibodies, Monoclonal
  • RNA, Viral
  • ibalizumab